Tuesday, June 5, 2012

5 Cash Heavy Large Cap Biotechnology Stocks That Analysts Rate As Buy


Biotech is a hot sector with high risk and high rewards, and when a biotech company has strong cash reserves, it has a unique advantage over its peers. Having cash to spend allows a company to invest in R&D, or make smart, strategic investments in innovative companies or technologies that could possibly fuel the next revolution in biotech. Today, we focus on biotech companies with plenty of cash, focusing further on those that analysts consider a 'Buy'.The Current ratio is a liquidity ratio used to determine a company's financial health. The metric illustrates how easily a company can pay back its short obligations all at once through current assets. A company that has a current ratio of one or less is generally a liquidity red flag. Now this doesn't mean the company will go bankrupt tomorrow, but it also doesn't bode well for the company, and may indicate that
... Read the rest at SeekingAlpha.com

No comments:

Post a Comment